TY - JOUR T1 - Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations JF - medRxiv DO - 10.1101/2021.02.05.21251118 SP - 2021.02.05.21251118 AU - Prajjval Pratap Singh AU - Rakesh Tamang AU - Manoj Shukla AU - Abhishek Pathak AU - Anshika Srivastava AU - Pranav Gupta AU - Alay Bhatt AU - Abhishek K. Shrivastava AU - Sudhir K. Upadhyay AU - Ashish Singh AU - Sanjeev Maurya AU - Purnendu Saxena AU - Vanya Singh AU - Akhilesh Kumar Chaubey AU - Dinesh Kumar Mishra AU - Yashvant Patel AU - Rudra Kumar Pandey AU - Ankit Srivastava AU - Nargis Khanam AU - Debashruti Das AU - Audditiya Bandopadhyay AU - Urgyan Chorol AU - Nagarjuna Pasupuleti AU - Sachin Kumar AU - Satya Prakash AU - Astha Mishra AU - Pavan Kumar Dubey AU - Ajit Parihar AU - Priyoneel Basu AU - Jaison J Sequeira AU - Lavanya KC AU - Vijayalaxmi Vijayalaxmi AU - Vishnu Shreekara Bhat.K AU - Thadiyan Parambil Ijinu AU - Dau Dayal Aggarwal AU - Anand Prakash AU - Kiran Yadav AU - Anupam Yadav AU - Vandana Upadhyay AU - Gunjan Mukim AU - Ankan Bhandari AU - Ankita Ghosh AU - Akash Kumar AU - Vijay Kumar Yadav AU - Kriti Nigam AU - Abhimanyu Harshey AU - Tanurup Das AU - Deepa Devadas AU - Surendra Pratap Mishra AU - Ashish Kumar AU - Abhay Kumar Yadav AU - Nitish Kumar Singh AU - Manpreet Kaur AU - Sanjay Kumar AU - Nikhil Srivastava AU - Charu Sharma AU - Ritabrata Chowdhury AU - Dharmendra Jain AU - Abhai Kumar AU - Ritesh Shukla AU - Raghav Kumar Mishra AU - Royana Singh AU - Yamini B Tripathi AU - Vijay Nath Mishra AU - Mohammed S. Mustak AU - Niraj Rai AU - Sumit Kumar Rawat AU - Prashant Survajhala AU - Keshav K singh AU - Chandana Basu Mallick AU - Pankaj Shrivastava AU - Gyaneshwer Chaubey Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/10/2021.02.05.21251118.abstract N2 - Infection born by Coronavirus SARS-CoV-2 has swept the world within a time of a few months. It has created a devastating effect on humanity with social and economic depression. Europe and America were the hardest hit continents. India has also lost lives, making the country fourth most deadly worldwide. However, the infection and death rate per million and the case fatality ratio in India were substantially lower than in many developed nations. Several factors have been proposed including genetics. One of the important facts is that a large chunk of Indian population is asymptomatic to the SARS-CoV-2 infection. Thus, the real infection in India is much higher than the reported number of cases. Therefore, the majority of people are already immune in the country. To understand the dynamics of real infection as well as the level of immunity against SARS-CoV-2, we have performed antibody testing (serosurveillance) in the urban region of fourteen Indian districts encompassing six states. In our survey, the seroprevalence frequency varied between 0.01-0.48, suggesting high variability of viral transmission between states. We also found out that the cases reported by the government were several fold lower than the real incidence of infection. This discrepancy is mainly driven by the higher number of asymptomatic cases. Overall, we suggest that with the high level of immunity developed against SARS-CoV-2 in the majority of the districts, the case fatality rate of second wave in India will be minor than first wave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding rceived for this specific work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is approved by the Ethical committe of Banaras Hindu University, Varanasi, IndiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available with the manuscript. ER -